CorMedix Inc.'s DefenCath reduces catheter infections by 71%, but the limited market potential challenges long-term adoption.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback